|
Post by bigmoneytex on Feb 24, 2015 20:51:20 GMT -5
from my discussion with the gentleman at mnkd technology it is limited by the 20mg dosing per cartridge more than anything else.
|
|
|
Post by zieg on Feb 24, 2015 20:59:01 GMT -5
I mentioned on another post under "Afrezza Script Counts" that I (through a mutual friend) spoke to a Sanofi Rep who is launching Afrezza in the Souther Il area. He is not a MNKD shareholder, so in kind of a tit for tat, I briefed him and brought him up to speed on MNKD and he did w/ Sanofi etc.
I just text him the updates from the conf call today.
Here is his response:
Great info! Thanks for sharing! Yes, from the Sanofi end of things, as I've said, the response has been overwhelmingly positive. I think our customers have realized that it is early and are excited about having all the resources that will be avail shortly. The 12 unit cartridge will be an important addition to reach the many patients on higher doses of mealtime insulin. Just had that discussion at lunch today with a key customer. The one thing that hasn't been realized is the patient demand for this product. Consumer awareness is going to drive this product. When DTC gets going, watch out!
|
|
|
Post by mnholdem on Feb 24, 2015 21:06:54 GMT -5
Liane, you nailed it a few days ago, alright, with your Debbie Downer call. BTW, where the hell is spiro? It can't take that long to walk an extra mile...even in my shoes!
|
|
|
Post by ashiwi on Feb 24, 2015 21:56:18 GMT -5
Spiro is too busy trying to figure out how to inhale with his new Dreamboat. Once he sells a few shares he's going to buy his continuous glucose monitor so he can tweet with Afrezzauser. If you noticed his Avatar, he traded in his cigar for a Dreamboat.
|
|
|
Post by saxcmann on Feb 24, 2015 23:59:51 GMT -5
"The 12 unit cartridge will be an important addition to reach the many patients on higher doses of mealtime."
...this is the only negative thing I've heard so far... the dosage is too low for many. This should be fixed soon tho.
|
|
|
Post by mnkdfan on Feb 25, 2015 1:12:58 GMT -5
Matt mentioned something about 9,000,0000 shares stock loan arrangement and not floating around and then returned. Can some of our local gurus please provide some insight to what Matt is talking about?
Thanks,
|
|
|
Post by ezrasfund on Feb 25, 2015 1:33:41 GMT -5
Matt mentioned something about 9,000,0000 shares stock loan arrangement and not floating around and then returned. Can some of our local gurus please provide some insight to what Matt is talking about? Thanks, I think Matt was talking about the B of A loan. The 9 million shares were given to B of A by MNKD as collateral for the loan; and apparently those shares were sold (short) by B of A. Those 9 million shares will have to be returned by B of A when the loan is repaid. Matt is saying that those shares will go back onto the shelf and not be sold into the open market, as they are restricted shares(?). At this late date at least they are limiting further dilution, and this may be the undoing of the shorts. Matt also said that there are no conversion rights remaining in the Deerfield deal.
|
|
|
Post by mannmade on Feb 25, 2015 8:40:55 GMT -5
And correct me if I am wrong.. BofA is set to return those shares in August.
|
|
|
Post by ezrasfund on Feb 25, 2015 9:20:39 GMT -5
Just a note on the B of A loan. Yes, those folks are evil, but when you think about it you realize they had to sell those 9 million shares short, and it must have been understood by MNKD. Those shares were collateral for the loan, but if the company was unable to pay back the loan they would be bankrupt and the shares would be worthless. So they can be sold and the cash held as collateral, but the shares cannot really be collateral themselves.
On the other hand, B of A has to buy those shares back, so they must decide if the stock price is headed past the level when they made the loan (the magic $6 spot?), which may be why they are maintaining a low price target for MNKD.
|
|
|
Post by mnkdfan on Feb 25, 2015 9:33:15 GMT -5
Ezra, thank you for the explanation. I would think BAC could also loan out the shares to be the shorts and collect a hefty premium too.
|
|
|
Post by ezrasfund on Feb 25, 2015 9:41:42 GMT -5
Ezra, thank you for the explanation. I would think BAC could also loan out the shares to be the shorts and collect a hefty premium too. They cannot lend the shares and still be hedging against the possibility of a MNKD loan default. If MNKD could not repay the loan the shares would be worthless, the shorts would return them, and B of A would be left without any collateral. Essentially the loan to MNKD is a vote of confidence that they will be able to repay, and so long MNKD. A hedge against a loan default must be short MNKD.
|
|
|
Post by babaoriley on Feb 25, 2015 12:29:29 GMT -5
For the longer term, I liked the call, for the shorter term, well: The shorts are gonna have their day Tonight. The Shorts are gonna have their way Tonight. The loyal longs all mumble, “Good call.” But when the market opens, They’ll hit a stone wall. Hope I've got that all wrong. Great call, Baba!!!! LOL, hard to remember the last time I was wrong.... but I do have a very poor memory.
|
|
|
Post by dreamboatcruise on Feb 25, 2015 14:43:58 GMT -5
I was initially pretty excited about the higher than anticipated demand for samples. However, I have thought of one scenario that might temper the enthusiastic interpretation. What if the demand for samples is being driven in part by worse than anticipated need for doctors to jump through hoops to get insurers to approve scripts. I think some doctors [doctors correct me if I'm wrong] might give patients a couple of ten day sample packs rather than one if they anticipate that approval from their insurance might drag out a week or more. I don't have much perspective on how long these requests take with insurers.
I'm always trying to keep my expectations in check, so looking at things from different angles. Bottom line... I guess only the real script counts will provide the definitive answer.
|
|
|
Post by jpg on Feb 25, 2015 15:20:40 GMT -5
I was initially pretty excited about the higher than anticipated demand for samples. However, I have thought of one scenario that might temper the enthusiastic interpretation. What if the demand for samples is being driven in part by worse than anticipated need for doctors to jump through hoops to get insurers to approve scripts. I think some doctors [doctors correct me if I'm wrong] might give patients a couple of ten day sample packs rather than one if they anticipate that approval from their insurance might drag out a week or more. I don't have much perspective on how long these requests take with insurers. I'm always trying to keep my expectations in check, so looking at things from different angles. Bottom line... I guess only the real script counts will provide the definitive answer. What is the patient going to do after being on a few '10 day packs'? You do this when you think your patient will be on the med long term regardless of how many pack you give. This is not a 5 day Zitromax pack of antibiotics. I have never ever given a 'sample' to a patient if I don't think it is something I am comfortable prescribing. That is, to me anyway, the biggest MD barrier. Once you start giving out samples you feel comfortable using the drug and tend to use it more and more. Like I said ad nauseam (sorry): there is an almost inexhaustible supply of type 2s who should be on an insulin but aren't because of the injections. Type 1's (especially if they have CGM) will be the poster boys of efficacy and ease of use while the type 2s will be the massive script numbers. They are synergistic. Giving out samples is the first most important step to being comfortable with the product. I put 'sample' in quotes because I don't do primary care but do regularly put patients on new meds in the hospital expecting them to go home and take them long term. One of the most painful things to start is insulin and I do it maybe 1/5 as often as I think it should be done (and I am talking of basal not prandial). Once you start treating a few patients from that other 4/5th of patients with Afrezza you are well down the path of treating 4/5 of those patients with Afrezza and eventually will use basal only after Afrezza no longer works. I see no possible way of spinning this into a negative whatsoever. MDs giving out more samples then predicted is just good news. Sometimes a cloud is simply a cloud.
|
|
|
Post by dreamboatcruise on Feb 25, 2015 15:35:44 GMT -5
jpg... I'm not implying that doctors would give out Afrezza sample packs without writing, or intending to write, a prescription. Just that maybe doctors are giving out more than 1 sample on average per patient given that some patients may require some back and forth with insurance to get approved. Listening to the two conference calls has done nothing but strengthened my belief, so I certainly am not saying I believe there is anything demonstrably negative. I'm just not jumping up and down about the sample comment quite as frenetically as I was yesterday. Will wait for the IMS data before breaking out in full happy dance. Though after the two calls there might be some more buying if any further dips occur.
|
|